GO curators for mouse genes have assigned the following annotations to the gene product of Erbb3. (This text reflects annotations as of Wednesday, January 23, 2013.) Summary from NCBI RefSeq
[Summary is not available for the mouse gene. This summary is for the human ortholog.] This gene encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers, including prostate, bladder, and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. One isoform lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported, but they have not been thoroughly characterized. [provided by RefSeq, Jul 2008]Summary text based on GO annotations supported by experimental evidence in mouse
Researchers have inferred from direct assay, that the gene product of Erbb3
Brown N et al. (2004) Embryo-uterine interactions via the neuregulin family of growth factors during implantation in the mouse. Biol Reprod, 71:2003-11. (PubMed:15306553)
Erickson SL et al. (1997) ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development, 124:4999-5011. (PubMed:9362461)
Fu AK et al. (2001) Cdk5 is involved in neuregulin-induced AChR expression at the neuromuscular junction. Nat Neurosci, 4:374-81. (PubMed:11276227)
Riethmacher D et al. (1997) Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature, 389:725-30. (PubMed:9338783)
Sakamoto K et al. (2010) Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer. Oncogene, 29:5359-69. (PubMed:20639901)